Wellington Management Group LLP Raises Stake in Scholar Rock Holding Corporation $SRRK

Wellington Management Group LLP increased its position in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 0.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,727,085 shares of the company’s stock after buying an additional 9,430 shares during the period. Wellington Management Group LLP owned about 5.52% of Scholar Rock worth $369,990,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. IFP Advisors Inc grew its position in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares in the last quarter. Allworth Financial LP purchased a new stake in Scholar Rock in the 2nd quarter worth about $35,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Scholar Rock during the fourth quarter valued at $30,000. Summit Securities Group LLC purchased a new position in Scholar Rock during the 4th quarter worth $31,000. Finally, EverSource Wealth Advisors LLC increased its position in Scholar Rock by 151.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after purchasing an additional 525 shares during the period. 91.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on SRRK shares. Citigroup boosted their price objective on shares of Scholar Rock from $58.00 to $60.00 and gave the company a “buy” rating in a report on Friday, August 7th. Wedbush restated an “outperform” rating and set a $64.00 target price on shares of Scholar Rock in a report on Friday, August 21st. BMO Capital Markets reissued an “outperform” rating and set a $76.00 price objective on shares of Scholar Rock in a research report on Friday, August 7th. Barclays increased their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, June 18th. Four equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Scholar Rock has a consensus rating of “Buy” and a consensus price target of $58.77.

Scholar Rock Price Performance

SRRK opened at $57.80 on Monday. Scholar Rock Holding Corporation has a 12 month low of $27.07 and a 12 month high of $61.76. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.02 and a quick ratio of 7.02. The business has a 50-day moving average of $53.07 and a two-hundred day moving average of $48.90. The stock has a market capitalization of $7.04 billion, a price-to-earnings ratio of -16.75 and a beta of 0.69.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Thursday, August 6th. The company reported ($0.84) EPS for the quarter, meeting the consensus estimate of ($0.84). During the same period in the previous year, the company earned ($0.98) EPS. On average, research analysts expect that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current year.

Insider Buying and Selling at Scholar Rock

In related news, Director Katie Peng sold 5,446 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total value of $293,430.48. Following the sale, the director directly owned 34,301 shares in the company, valued at $1,848,137.88. The trade was a 13.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey S. Flier sold 3,053 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $164,495.64. Following the completion of the sale, the director owned 27,856 shares of the company’s stock, valued at approximately $1,500,881.28. This trade represents a 9.88% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 17,149 shares of company stock valued at $923,108. 10.30% of the stock is currently owned by company insiders.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).